AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France

Extended lab space for product development, customer demos, and training

Bachem expands multi-site production capacities to meet rising demand

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda

In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025

Prime Minister launches expansion of health coverage for citizens of and above 70 years

Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age

Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment